4 results about "Urinary excretion" patented technology

The present disclosure features imaging media including a contrast agent encapsulated within a biodegradable nanoparticle matrix. The particles are sized such that they avoid excretion via urinary excretion (e.g., at least 5 nm in diameter) during an imaging procedure or an image-guided procedure. Instead, the particles are predominantly removed from circulation by the reticuloendothelial system of the liver. This results in a buildup of contrast agent in the liver, allowing for a highly specific imaging modality for liver imaging. Further, the bulk of the imaging media is excreted into the bowel, reducing in-vivo toxicity of the imaging media. Finally, because of their size, the nanoparticles of the imaging media have a higher circulation half-life.

[Problem] An object of the present invention is to provide a method of estimating / evaluating a urinary excreted substance amount per unit time based on a finding that a urinary substance concentration can be quite accurately and practically estimated by considering an estimated glomerular filtration rate and a net urinary substance excretion rate. [Solution] The method of evaluating a urinary substance excretion amount per unit time includes: multiplying a concentration of an arbitrary urinary excreted substance present in the serum by: an estimated glomerular filtration rate per unit time, a numerical value (net urinary substance excretion rate) obtained by dividing a clearance of the arbitrary urinary excreted substance present in the serum by a glomerular filtration rate, and a predetermined coefficient.

Embodiments include systems and methods for treating diseases of the bladder, kidney, and urinary tract. The pharmaceutical product may be administered through the urethra in compacted form. Within the bladder, the product may expand or conform to a larger size, which prevents access into the urethra within a desired residence period. After the treatment period, at least a portion of the product may be dissolved or degraded such that individual particles excrete with urine. Embodiments also include drug particle delivery devices and methods of intravesical administration. The delivery device may use a drug-loaded cannula cartridge filled with a rod-like product that is administered into the bladder of a patient by actuation of a pressure source or a piston. The distal end of the barrel may be connected to a bladder sheath or a soft tip for direct insertion into the urethra of the patient.

The application discloses a medical control device and application thereof, which is used for controlling urethra and comprises a liquid bag, a connecting pipe, an expansion part and a support. The expansion part is arranged on the support, the support is used for being connected with a part to be controlled and making the expansion part contact with the part to be controlled. One end of the connecting pipe is communicated with the liquid bag, and the other end is communicated with the expansion part. Liquid outlet control parts and liquid return control parts are arranged on the liquid bag. The liquid outlet control parts and the liquid return control parts make liquid flow between the liquid bag and the connecting pipe. The medical control device is used as an artificial urethral sphincter. Urinary control and urinary excretion are realized through the liquid outlet control parts and the liquid return control parts respectively. Once operation can realize pressure increase or pressure release. The operation is simple, and urinary control and urinary excretion are more convenient. Meanwhile, the liquid bag can avoid being in an expanded state for a long time, and the service life of the liquid bag is prolonged.